Immunomodulatory effects of antileishmanial drugs

MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets

(2012) Juan C. Stockert et al.   ACTA HISTOCHEMICA

Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL/6 mice

(2012) Charlene Barreto Ponte et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9

(2012) Asok Kumar Mukherjee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro

(2012) S. Das et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Combination Therapy with Paromomycin-Associated Stearylamine-Bearing Liposomes Cures Experimental Visceral Leishmaniasis through Th1-Biased Immunomodulation

(2011) Antara Banerjee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids

(2010) José M Jiménez-López et al.   Lipids in Health and Disease

Designing Therapies against Experimental Visceral Leishmaniasis by Modulating the Membrane Fluidity of Antigen-Presenting Cells

(2009) S. Banerjee et al.   INFECTION AND IMMUNITY

Miltefosine Promotes IFN- -Dominated Anti-Leishmanial Immune Response

(2009) P. Wadhone et al.   JOURNAL OF IMMUNOLOGY

Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres

(2008) Prabhakar Reddy Veerareddy et al.   JOURNAL OF DRUG TARGETING